Rheumazentrum Ruhrgebiet, Ruhr Universität Bochum, Claudiusstr.45, 44649, Herne, Germany.
Arthritis Res Ther. 2024 Jul 26;26(1):141. doi: 10.1186/s13075-024-03365-y.
In spondyloarthritides (SpA) and fibromyalgia (FM), patients suffer from generalized pain. The impact of FM on PRO validated in SpA has not been systematically studied.
Study the performance of PROs developed for SpA in patients with primary (p) FM without chronic inflammatory-rheumatic disease vs. SpA without and with concomitant (c) FM.
Patients with pFM, axSpA or PsA and indication for treatment adaptation were prospectively included. Standardized PROs were assessed: BASDAI, ASDAS-CRP, DAPSA, patient´s global assessment, BASFI, LEI, MASES, SPARCC Enthesitis Score and FIQ.
300 patients were included (100/diagnosis). More males were found in axSpA vs. PsA and pFM group (67, 33 and 2/100, respectively), while 12 axSpA (axSpA+) and 16 PsA (PsA+) patients had cFM. pFM patients showed significantly higher scores in all assessments vs. axSpA or PsA, with exception of ASDAS-CRP (3.3 ± 0.6 in FM vs. 3.1 ± 1.0 in axSpA) and duration of low lumbar morning stiffness. Similar results were also found in the subanalysis of female patients only. In addition, patients with axSpA + or PsA + showed no differences to patients with pFM, while significantly higher scores were found for FM, axSpA + and PsA + for almost all FIQ items compared to axSpA- or PsA-.
PROs originally developed for axSpA or PsA need to be interpreted differently in the presence or absence of cFM. ASDAS-CRP and duration of lumbar morning stiffness were not affected by cFM. FM-specific questionnaires also showed high scores in patients with SpA with cFM but not in those without.
在脊柱关节炎(SpA)和纤维肌痛(FM)中,患者会遭受全身性疼痛。尚未系统研究 FM 对 SpA 中患者报告结局(PRO)的影响。
研究专门为 SpA 开发的 PRO 在原发性(p)纤维肌痛而无慢性炎症性风湿病患者与 SpA 无和伴发(c)纤维肌痛患者中的表现。
前瞻性纳入患有 pFM、轴性 SpA 或银屑病关节炎且需要治疗调整的患者。评估了标准化的 PRO:BASDAI、ASDAS-CRP、DAPSA、患者整体评估、BASFI、LEI、MASES、SPARCC 附着点炎评分和 FIQ。
共纳入 300 例患者(100/诊断)。与 PsA 和 pFM 组相比,在 axSpA 中发现更多的男性(67、33 和 2/100),而 12 例 axSpA(axSpA+)和 16 例 PsA(PsA+)患者伴发 cFM。与 axSpA 或 PsA 相比,pFM 患者在所有评估中得分显著更高,除了 ASDAS-CRP(FM 中为 3.3±0.6,axSpA 中为 3.1±1.0)和低腰椎晨僵时间。在仅女性患者的亚分析中也发现了类似的结果。此外,axSpA+或 PsA+患者与 pFM 患者无差异,而 FM、axSpA+和 PsA+患者在几乎所有 FIQ 项目中的得分均显著高于 axSpA-或 PsA-患者。
专门为 axSpA 或 PsA 开发的 PRO 在伴发或不伴发 cFM 时需要以不同的方式解释。cFM 不影响 ASDAS-CRP 和腰椎晨僵时间。在伴发 cFM 的 SpA 患者中,纤维肌痛特异性问卷也显示出较高的得分,但在不伴发 cFM 的患者中则没有。